<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003788</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066927</org_study_id>
    <secondary_id>HEALTHONE-43892</secondary_id>
    <secondary_id>HEALTHONE-1A</secondary_id>
    <secondary_id>HEALTHONE-CA43892</secondary_id>
    <secondary_id>RPCI-DS-9802</secondary_id>
    <secondary_id>NCI-V99-1525</secondary_id>
    <nct_id>NCT00003788</nct_id>
  </id_info>
  <brief_title>Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas</brief_title>
  <official_title>Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Health Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill tumor cells. It is not yet known if the addition of photodynamic therapy to&#xD;
      combined therapy with surgery, radiation therapy, and chemotherapy is more effective than&#xD;
      combined therapy alone for supratentorial gliomas.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to study the effectiveness of surgery, radiation therapy,&#xD;
      and chemotherapy with or without photodynamic therapy in treating patients who have newly&#xD;
      diagnosed or recurrent malignant supratentorial gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether the addition of photodynamic therapy to standard brain tumor care&#xD;
           (surgical resection, postoperative radiotherapy, and chemotherapy) will result in a&#xD;
           significant prolongation of time to recurrence and survival in newly diagnosed malignant&#xD;
           supratentorial gliomas.&#xD;
&#xD;
        -  Compare the effect of high or low light dose photodynamic therapy on survival of&#xD;
           patients with recurrent malignant supratentorial gliomas.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter, two part study. Patients are stratified according&#xD;
      to clinical center.&#xD;
&#xD;
      Newly diagnosed patients (Study 1)&#xD;
&#xD;
        -  Patients are randomized to receive either high light dose photodynamic therapy (arm I)&#xD;
           or no photodynamic therapy (arm II):&#xD;
&#xD;
             -  Arm I: Patients receive porfimer sodium (Photofrin) IV one day prior to surgery.&#xD;
                Craniotomy and tumor resection are performed. Upon completion of resection,&#xD;
                patients undergo intracavitary photoillumination with a high light dose.&#xD;
&#xD;
             -  Arm II: Craniotomy and tumor resection are performed. Postoperatively, all patients&#xD;
                receive external beam radiotherapy 5 days per week for 5-6 weeks. After completing&#xD;
                radiotherapy, patients receive nitrosourea (carmustine or lomustine) chemotherapy.&#xD;
&#xD;
      Recurrent tumor patients (Study 2)&#xD;
&#xD;
        -  Patients receive Photofrin IV one day prior to surgery. Craniotomy and tumor resection&#xD;
           are performed.&#xD;
&#xD;
             -  Arm I: Patients receive high dose light therapy during surgery.&#xD;
&#xD;
             -  Arm II: Patients receive low dose light therapy during surgery. Patients receive&#xD;
                chemotherapy with procarbazine for 28 days beginning 2-4 weeks after surgery.&#xD;
                Courses repeat every 56 days in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
      Patients are followed on both studies at 4 weeks postsurgery, then every 3 months until death&#xD;
      or for 1 year after study closure.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 150 patients with newly diagnosed tumor will be accrued for&#xD;
      this study within 4 years (Study 1). A maximum of 120 patients with recurrent disease will be&#xD;
      accrued within 4.5 years (Study 2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed or recurrent supratentorial glioblastoma or&#xD;
             malignant astrocytoma&#xD;
&#xD;
               -  Grade 3 or 4 astrocytoma as defined by the Daumas-Duport classification&#xD;
&#xD;
          -  Suitable for radical resection on the basis of imaging studies&#xD;
&#xD;
          -  Patients with recurrent disease must have failed surgery and radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100% for newly diagnosed tumor&#xD;
&#xD;
          -  Karnofsky 70-100% for recurrent tumor&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Recurrent tumor:&#xD;
&#xD;
               -  WBC at least 2,000/mm^3&#xD;
&#xD;
               -  Platelet count at least 80,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Recurrent tumor:&#xD;
&#xD;
               -  PT/PTT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin and LFTs less than 2 times ULN&#xD;
&#xD;
               -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
               -  GGT no greater than 3 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior cranial radiotherapy for newly diagnosed tumor&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred W. Hetzel, PhD, JD</last_name>
    <role>Study Chair</role>
    <affiliation>Colorado Health Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Neurological Associates</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital-Annex</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

